Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from ViiV Healthcare

< Previous 1 2 Next >
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switch
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study.... 
Tickers PFE
From Business Wire News Releases
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted... 
Tickers PFE
From Business Wire News Releases
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
ViiV HC submits New Drug Application to US FDA for first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV 
Tickers PFE
From Business Wire News Releases
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
ViiV Healthcare announces FDA approval of Dovato for treatment-naive adults with HIV-1 
Tickers PFE
From Business Wire News Releases
ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three
ViiV HC presents positive data showing once monthly, two-drug, long-acting injectable as effective as daily, three-drug oral treatment for HIV 
Tickers PFE
From Business Wire News Releases
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks 
Tickers GSK PFE
From Business Wire News Releases
ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïv
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads 
Tickers GSK PFE
From Business Wire News Releases
ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 2018
The data focuses on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding 
Tickers PFE
From Business Wire News Releases
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration... 
Tickers GSK PFE
From PR Newswire
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
Tickers GSK PFE
From PR Newswire
Is Complacency the New HIV crisis?
Tickers PFE
From PR Newswire
ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment
Tickers GSK PFE
From PR Newswire
ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV
Tickers GSK PFE
From PR Newswire
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
Tickers GSK PFE
From PR Newswire
ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir
Tickers GSK PFE
From PR Newswire
ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment
Tickers GSK PFE
From PR Newswire
ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists
Innovative collaboration aims to help cultivate the next generation of HIV physicians with a focus on underserved communities 
Tickers GSK PFE
From PR Newswire
ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection
Tickers GSK PFE
From PR Newswire
Almost half of Canadians have never been tested for HIV
From PR Newswire
ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy
Tickers GSK PFE
From PR Newswire
ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally
Tickers GSK PFE
From PR Newswire
New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression
Tickers GSK PFE
From PR Newswire
Media Advisory - ViiV Healthcare Media Interviews
From PR Newswire
ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries
Tickers GSK PFE
From PR Newswire
ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV
Tickers GSK GSK PFE
From PR Newswire
ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy
Tickers GSK GSK PFE
From PR Newswire
ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men
Initial Investment to Help Research, Identify and Apply Innovative Solutions in Baltimore, Maryland and Jackson, Mississippi - Two of the Cities Hardest Hit by HIV/AIDS 
Tickers GSK GSK PFE
From PR Newswire
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
Tickers GSK GSK MYL PFE
From PR Newswire
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.
Positive Action Southern Initiative Commitment Continues with New Grants Awarded to Seven Organizations, Bringing Total Funding for Grassroots Projects to More than 2.8 Million to Date 
Tickers GSK GSK PFE
From PR Newswire
Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information. Please click:... 
Tickers GSK GSK PFE PFZ
From PR Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.